Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVERDOUX, Helene
dc.contributor.authorQUILES, Clelia
dc.contributor.authorDE LEON, J.
dc.date.accessioned2020-07-16T13:16:02Z
dc.date.available2020-07-16T13:16:02Z
dc.date.issued2019-09
dc.identifier.issn0920-9964en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10498
dc.description.abstractEnOBJECTIVES: To identify the clinical determinants of fever in clozapine users and their impact on management of clozapine treatment. METHODS: Articles published in English or French identified with a MEDLINE, Web of Sciences, Cochrane Library and PsycINFO search, from inception through February 2019, using the term "clozapine" in combination with "fever" OR "hyperthermia" OR "body temperature" OR "pyrexia" OR "febrile" OR "heat" OR "thermoregulation". Information extracted for each medical condition were frequency, time to onset after initiation of clozapine treatment, characteristics of fever, associated symptoms, laboratory tests used for diagnosis, course, lethality, discontinuation of clozapine. Data were synthesized narratively. RESULTS: Our search yielded 394 unique hits published from 1993 to 2018. We included 73 articles in the review: two meta-analyses, 14 reviews, six epidemiological studies, 11 clinical studies and 40 case reports. During clozapine initiation, fever is most frequently benign and transient but should be closely monitored as it may be the first stage of potentially life-threatening adverse drug reactions (ADR) (agranulocytosis, neuroleptic malignant syndrome myocarditis, hepatitis, pancreatitis, nephritis, colitis, etc.). Other ADR associated with fever are independent of duration of exposure to clozapine (heat stroke, pneumonia, pulmonary embolism, necrotizing colitis). If fever is due to intercurrent infection, therapeutic drug monitoring is recommended to adjust clozapine daily dosage. CONCLUSION: Benign causes of fever are much more frequent than life-threatening ADR during clozapine treatment. Discontinuation should not be considered as automatic in the event of fever, especially during the early phase of clozapine initiation.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enClinical determinants of fever in clozapine users and implications for treatment management: A narrative review
dc.title.alternativeSchizophr Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.schres.2019.07.040en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31378552en_US
bordeaux.journalSchizophrenia Researchen_US
bordeaux.page1-9en_US
bordeaux.volume211en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209306
hal.version1
hal.date.transferred2021-04-27T08:35:20Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Schizophrenia%20Research&rft.date=2019-09&rft.volume=211&rft.spage=1-9&rft.epage=1-9&rft.eissn=0920-9964&rft.issn=0920-9964&rft.au=VERDOUX,%20Helene&QUILES,%20Clelia&DE%20LEON,%20J.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée